Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensifentrine Phase 3 in moderate to severe COPD (ENHANCE-2)
NCT04542057Phase 3Completed
- Sponsor
- Verona Pharma
- Start
- Sep 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of ensifentrine in chronic obstructive pulmonary disease (COPD), sponsored by Verona Pharma. Started Sep 2020; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04542057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542057.